Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS

Sanofi company Genzyme has entered a collaboration with Cambridge, Massachusetts-based Voyager Therapeutics focused on the discovery of gene therapies for severe CNS disorders.